Hjem
Olav Dahls bilde

Olav Dahl

Professor
  • E-postOlav.Dahl@uib.no
  • Telefon+47 55 97 20 18
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2015. Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. Acta Oncologica. 470-479.
  • 2015. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • 2014. Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology. 352-358.
  • 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4. Human Molecular Genetics. 3373-3380.
  • 2013. Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncologica. 736-744.
  • 2013. Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Human Reproduction. 1995-2002.
  • 2013. Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort. Radiotherapy and Oncology. 55-60.
  • 2012. The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 157-163.
  • 2012. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. British Journal of Cancer. 1833-1839.
  • 2012. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. International Journal of Hyperthermia. 549-553.
  • 2012. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Human Reproduction. 1525-1535.
  • 2012. Fibroblast growth factor 2—A predictor of outcome for patients irradiated for stage II-III non–small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 442-447.
  • 2012. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 1684-1691.
  • 2012. Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National Cohort. International Journal of Radiation Oncology, Biology, Physics. E173-E180.
  • 2011. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 499-505.
  • 2011. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular cancer group. Journal of Clinical Oncology. 2032-2039.
  • 2011. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group. Journal of Clinical Oncology. 719-725.
  • 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 sider.
  • 2010. Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie und Onkologie (Print). 307-314.
  • 2010. Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. European Urology. 134-140.
  • 2010. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Annals of Oncology. 1858-1863.
  • 2010. Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 1005-1011.
  • 2010. A study of coping in long-term testicular cancer survivors. Psychology, Health & Medicine. 146-158.
  • 2009. cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 1562-1569.
  • 2009. Utilisation of specialist care in patients with incurable rectal cancer. A population-based study from Western Norway. Acta Oncologica. 377-384.
  • 2009. Topographical distribution of choroidal naevi in the ocular fundus. Eye (London. 1987). 1685-1690.
  • 2009. The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors. Acta Oncologica. 842-849.
  • 2009. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nature Genetics. 1238-1242.
  • 2009. Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program. Journal of Clinical Oncology. 2122-2128.
  • 2009. Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 838-844.
  • 2009. Pulmonary Function in Long-Term Survivors of Testicular Cancer. Journal of Clinical Oncology. 2779-2786.
  • 2009. Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy. Acta Oncologica. 874-881.
  • 2009. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 1682-1695.
  • 2009. Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 41-46.
  • 2009. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by The European Society for Hyperthermic Oncology. International Journal of Hyperthermia. 323-334.
  • 2009. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 368-376.
  • 2009. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 580-588.
  • 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • 2009. Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. European Journal of Cancer. 2383-2390.
  • 2008. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 128-137.
  • 2008. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 128-137.
  • 2008. Posterior uveal melanoma. Distribution of the sites of origin and patterns of tumour extent in the ocular fundus. British Journal of Ophthalmology. 751-756.
  • 2008. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye (London. 1987). 1398-1403.
  • 2008. Palliative surgery for rectal cancer in a national cohort. Colorectal Disease. 336-343.
  • 2008. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. International Journal of Radiation Oncology, Biology, Physics. 1478-1486.
  • 2008. Incidence of iris melanoma in western Norway. Acta Ophthalmologica. 116-117.
  • 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • 2008. Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 425-441.
  • 2008. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 1264-1273.
  • 2008. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology.
  • 2008. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 1257-1264.
  • 2008. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncologica. 1257-1264.
  • 2008. Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 97-110.
  • 2008. Chronic cancer-related fatigue in long-term survivors of testicular cancer. Journal of Psychosomatic Research. 363-371.
  • 2007. Transient neurological adverse effects following low dose radiation therapy for early stage testicular seminoma. Radiotherapy and Oncology. 137-144.
  • 2007. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncologica. 639-650.
  • 2007. Strålebehandling av endetarmskreft. Tidsskrift for Den norske legeforening. 3090-3093.
  • 2007. Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin. Scandinavian Journal of Immunology. 192-201.
  • 2007. Is the sexual function compromised in long-term testicular cancer survivors? European Urology. 1438-1447.
  • 2007. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncologica. 480-489.
  • 2007. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology. 241-248.
  • 2007. Clinical characteristics and outcomes in patients with advanced rectal cancer: A national prospective cohort study. Diseases of the Colon & Rectum. 285-291.
  • 2007. Adjuvant kjemoterapi ved tykktarmskreft. Tidsskrift for Den norske legeforening. 3094-3096.
  • 2006. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica. 454-462.
  • 2006. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology.
  • 2006. A concomitant tumour boost in bladder irradiation: Patient suitability and the potential of intensity-modulated radiotherapy. Radiotherapy and Oncology. 98-105.
  • 2005. The assosiation between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men i general population sample. Supportive Care in Cancer. 637-646.
  • 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorders in long-term survivors of testicular cancer and men in the general population sample. Supportive Care in Cancer. 637-646.
  • 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 637-646.
  • 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 637-646.
  • 2005. Testing the new ICRU 62 'Planning Organ at Risk Volume' concept for the rectum. Radiotherapy and Oncology. 293-302.
  • 2005. Study of anxiety disorder and depression in long-term survivors of testicular cancer. Journal of Clinical Oncology. 2389-2395.
  • 2005. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. Journal of Clinical Oncology. 3061-3068.
  • 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • 2005. Paternity Following Treatment for Testicular Cancer. Journal of the National Cancer Institute. 1580-1588.
  • 2005. Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology. 4980-4990.
  • 2005. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • 2005. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • 2004. Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology. 107-113.
  • 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • 2004. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • 2004. On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiotherapy and Oncology. 11-19.
  • 2004. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurologica Scandinavica. 378-384.
  • 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • 2004. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: A pilot study of eight stool markers. Scandinavian Journal of Gastroenterology. 1113-1118.
  • 2004. Evaluation of a new method for calculation of cumulative doses in the rectum wall using repeat CT scans. Acta Oncologica. 388-395.
  • 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • 2004. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiotherapy and Oncology. 43-53.
  • 2004. A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of equivalent uniform doses and the volume parameter. Physics in Medicine and Biology. 3341-3352.
  • 2003. The level of physical activity in long-term survivors of testicular cancer. European Journal of Cancer. 1216-1221.
  • 2003. The level of physical activity in long-term surdivors of testicular cancer. European Journal of Cancer. 6 sider.
  • 2003. Sustained Prothrombotic profile after Hip Replacement Surgery. The Influence of Prolonged Prophylaxis with Dalteparin. Thrombosis and Haemostasis. 971-975.
  • 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • 2003. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • 2003. Gonadal hormones in longterm survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 7 sider.
  • 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • 2003. Brachytherapy for prostatic cancer: a systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • 2003. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • 2002. The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters. 209-217.
  • 2002. Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 562-565.
  • 2002. Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. International Journal of Hyperthermia. 141-152.
  • 2002. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 173-183.
  • 2002. Brakyterapi ved prostatakreft. Tidsskrift for Den norske legeforening. 2795-2798.
  • 2001. Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology, Biology, Physics. 535-544.
  • 2001. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 313-320.
  • 2001. Partially wedged beams improve radiotherapy treatment of urinary bladder cancer. Radiotherapy and Oncology. 21-30.
  • 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • 2001. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. International Journal of Radiation Oncology, Biology, Physics. 1159-1166.
  • 2001. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 147-154.
  • 2001. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 11 sider.
  • 2001. Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters. International Journal of Radiation Oncology, Biology, Physics. 627-637.
  • 2001. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet. 1291-1304.
  • 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • 2000. Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • 2000. Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • 2000. Dose-volume analysis of different stereotactic radiotherapy mono-isosentric techniques. Acta Oncologica. 157-163.
  • 2000. Dose-volume analysis of different stereotactic radiotherapy mono-isocentric techniques. Acta Oncologica. 157-163.
  • 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • 1999. Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • 1999. Tissue Prostate-Specific Antigen and Androgen Receptor Immunoreactivity in Prostate Cancer Biopsies before, during and after Neo-Adjuvant Androgen Deprivation Followed by Radiotherapy. European Urology. 116-122.
  • 1999. Tissue PSA and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • 1999. Status of clinical hyperthermia. Acta Oncologica. 863-873.
  • 1999. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by EORTC. Radiotherapy and Oncology. 149-156.
  • 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • 1997. for the Swedish-Norwegian Testis Cancer Group (SWENOTECA). European Journal of Cancer. 1038-1044.
  • 1997. Risk-adapted treatment of clinical stage I nonseminoma testis cancer. European Journal of Cancer. 1038-1044.
  • 1997. Risk-adapted treatment of clinical stage I non-seminaoma testis cancer. European Journal of Cancer. 1038-1044.
  • 1997. Quality assurance in conformal radiotherapy. DYNARAD consensus report on pratice guidelines. Radiotherapy and Oncology. 217-223.
  • 1997. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. British Journal of Cancer. 1744-1762.
  • 1997. Fibrosarcoma in children. A rare tumour with long-term survival even with advanced disease. A report of 3 cases. Acta Oncologica. 438-440.
  • 1997. Fibrosarcoma in children. Acta Oncologica. 438-440.
  • 1996. Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. International Journal of Radiation Oncology, Biology, Physics. 403-415.
  • 1996. Clinical assessment of conformal radiotherapy results. Acta Oncologica. 41-57.
  • 1996. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica. 759-761.
  • 1995. The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. European Journal of Cancer. 1785-1789.
  • 1995. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. The Lancet. 540-543.
  • 1993. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater - Results of a controlled, prospective, randomised multicentre study. European Journal of Cancer. 698-703.
  • 1978. A syndrome of factor VVI deficiency and abnormal platelet release reaction. Scandinavian Journal of Haematology. 206-214.
Vitenskapelig foredrag
  • 2014. Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
  • 2006. The present conditions and the future prospects of clinical test of hyperthermia in Europe.
  • 2006. Posterior uveal melanoma. Distribution of initiation sites and patterns of tumour extent in the ocular fundus.
  • 2005. Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer.
  • 2005. Får pasienter med lokalisert prostatakreft adekvat tilbud om radikal strålebehandling?
  • 2005. A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
  • 2005. A concomitant tumour boost in bladder irradiation: Patient suitability and the potensial of intensity-modulated radiotherapy.
  • 2004. Post-treatment paternity in testicular cancer survivors.
  • 2004. Post-treatment paternity in testicular cancer survivors.
  • 2004. Dose response in a series of 495 patients with early prostate cancer.
  • 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors.
  • 2004. Blood pressure and Body mass index in testicular cancer survivors.
  • 2004. A test of the ICRU 62 "Planning organ at Risk Volume" concept for the rectum.
  • 2004. A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of the equivalent uniform doses and the volume parameter.
  • 2003. Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
  • 2003. Only colon cancer patients with Dukes stage C benefit from adjuvant chemotherapy with 5-fluorouracil and levamisole among 425 patients with operable colorectal cancer in a Norwegian randomised study.
  • 2003. Adjuvant chemotherapy in colorectal cancer: Joint analyses of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
  • 2001. Verification of a 3-D treatment planning system for episcleral brachytherapy.
  • 2001. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer.
Sammendrag/abstract
  • 2014. Scandinavian studies of gene variants and risk of testicular germ cell tumor. 8th CIS Abstract book.
  • 2014. Particle therapy in Norway - report from the national project group. Radiotherapy and Oncology. 314-314.
  • 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in the tumor suppressor gene SPRY4. Norsk Epidemiologi, Supplement. 44-44.
  • 2012. Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. Journal of Clinical Oncology. 1 sider.
  • 2009. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. Journal of Clinical Oncology. 2 sider.
  • 2008. Topographical distribution of posterior uveal melanoma, choroidal nevi, and congenital hypertrophy of the retinal pigment epithelium. Acta Ophthalmologica. 8-8.
  • 2008. Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 23 sider.
  • 2008. Pulmonary function in long-term testicular cancer survivors. Annals of Oncology. viii205.
  • 2007. Is neuroticism associated with long-term morbidity in testicular cancer survivors? Psycho-Oncology.
  • 2007. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology.
  • 2006. Self-reported paresthesias, Raynaud's phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TG) survivors. Journal of Clinical Oncology. 228S-228S.
  • 2006. Self-reported paresthesia, Raynaud,s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. Journal of Clinical Oncology. 228s.
  • 2006. Cardiovascular (CV)morbidity and predicted mortality in long-term testicular cancer (TC) survivors. Annals of Oncology. 443PD.
  • 2005. Self-reported paresthesia, Raynaud’s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. European Journal of Cancer.
  • 2005. Metabolic syndrome in long-term testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology.
  • 2005. Metabolic syndrome in long-term testicular cancer survivors. Journal of Clinical Oncology.
  • 2005. Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer. European Journal of Cancer. 228s.
  • 2004. Working ability and educational level among long-term survivors of teasticular cancer (TCSS) compared to a general population (GenPop). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
  • 2004. Testing the new ICRU 62 'planning organ at risk volume' concept for the rectum. Radiotherapy and Oncology.
  • 2004. Post-treatment paternity in testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
  • 2004. Post-treatment paternity in testicular cancer survivors. Journal of Clinical Oncology. 388S-388S.
  • 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • 2003. Treatment precision and treatment effect in conformal radiotherapy of urinary bladder cancer - preliminary results. Radiotherapy and Oncology. S94-S94.
  • 2003. Risk-adapted brief adjuvant chemotherapy in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 sider.
Vitenskapelig oversiktsartikkel/review
  • 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • 2008. Analkreft. 198-200.
  • 2004. Conformal radiotherapy of urinary bladder cancer. 387-398.

Se fullstendig oversikt over publikasjoner i CRIStin.